ABSTRACT
OBJECTIVE: Evaluate the ability of an extended version of the 3 MTM Eargage to estimate the earcanal size and assess the likelihood that a particular earplug can fit an individual's earcanal, ultimately serving as a tool for selecting earplugs in the field. DESIGN: Earcanal morphology, assessed through earcanal earmolds scans, is compared to earcanal size assessed with the extended eargage (EE) via box plots and Pearson linear correlations coefficients. Relations between attenuation measured on participants (for 6 different earplugs) and their earcanal size assessed with the EE are established via comparison tests. STUDY SAMPLE: 121 participants exposed to occupational noise (103 men, 18 women, mean age 47 years). RESULTS: The earcanal size assessed with the EE allows for estimating the area of the earcanal's first bend cross-section (correlation coefficient r = 0.533, p < 0.001). Extremely large earcanals (12.7% of earcanals in our sample) lead to significantly lower earplug attenuation (potentially inadequate) than smaller earcanals. CONCLUSIONS: The EE is a simple and inexpensive tool easily deployable in the field to assist earplugs selection. When extended with sizes larger than the maximum size of the commercial tool, it allows for detecting individuals with extremely large earcanals who are most likely to be under-protected.
ABSTRACT
Offering hearing protection devices (HPDs) to workers exposed to hazardous noise is a noise control strategy often used to prevent noise-induced hearing loss (NIHL). However, HPDs are used incorrectly and inconsistently, which explains their limited efficiency. Numerous models based on social cognition theories identify the significant factors associated with inconsistent HPD use and aim to improve HPD training programs and to increase HPD use. However, these models do not detail (dis)comfort aspects originating from complex interactions between characteristics of the triad "environment/person/HPD" while these aspects are known to largely influence HPD (mis)use. This paper proposes a holistic model explaining HPD (mis)use, based on the integration of a comfort model adapted to HPDs into an existing behavioral model already developed for HPDs. The model also takes into account the temporal dimension, which makes it possible to capture the scope of change in HPD-related health behaviors. This holistic description of HPD use could be used as a tool for stakeholders involved in HPD use to effectively prevent NIHL among workers.
Subject(s)
Hearing Loss, Noise-Induced , Noise, Occupational , Occupational Exposure , Ear Protective Devices , Hearing , Hearing Loss, Noise-Induced/prevention & control , Humans , Noise, Occupational/adverse effects , Noise, Occupational/prevention & control , Occupational Exposure/analysisABSTRACT
This study investigated the effect of decaffeinated green tea extract (dGTE), with or without antioxidant nutrients, on fat oxidation, body composition and cardio-metabolic health measures in overweight individuals engaged in regular exercise. Twenty-seven participants (20 females, 7 males; body mass: 77.5 ± 10.5 kg; body mass index: 27.4 ± 3.0 kg·m2; peak oxygen uptake (O2peak): 30.2 ± 5.8 mL·kg-1·min-1) were randomly assigned, in a double-blinded manner, either: dGTE (400 mg·d-1 (-)-epigallocatechin-3-gallate (EGCG), n = 9); a novel dGTE+ (400 mg·d-1 EGCG, quercetin (50 mg·d-1) and α-lipoic acid (LA, 150 mg·d-1), n = 9); or placebo (PL, n = 9) for 8 weeks, whilst maintaining standardised, aerobic exercise. Fat oxidation ('FATMAX' and steady state exercise protocols), body composition, cardio-metabolic and blood measures (serum glucose, insulin, leptin, adiponectin, glycerol, free fatty acids, total cholesterol, high [HDL-c] and low-density lipoprotein cholesterol [LDL-c], triglycerides, liver enzymes and bilirubin) were assessed at baseline, week 4 and 8. Following 8 weeks of dGTE+, maximal fat oxidation (MFO) significantly improved from 154.4 ± 20.6 to 224.6 ± 23.2 mg·min-1 (p = 0.009), along with a 22.5% increase in the exercise intensity at which fat oxidation was deemed negligible (FATMIN; 67.6 ± 3.6%O2peak, p = 0.003). Steady state exercise substrate utilisation also improved for dGTE+ only, with respiratory exchange ratio reducing from 0.94 ± 0.01 at week 4, to 0.89 ± 0.01 at week 8 (p = 0.004). This corresponded with a significant increase in the contribution of fat to energy expenditure for dGTE+ from 21.0 ± 4.1% at week 4, to 34.6 ± 4.7% at week 8 (p = 0.006). LDL-c was also lower (normalised fold change of -0.09 ± 0.06) for dGTE+ by week 8 (p = 0.038). No other significant effects were found in any group. Eight weeks of dGTE+ improved MFO and substrate utilisation during exercise, and lowered LDL-c. However, body composition and cardio-metabolic markers in healthy, overweight individuals who maintained regular physical activity were largely unaffected by dGTE.
Subject(s)
Adipose Tissue/drug effects , Antioxidants/administration & dosage , Overweight/therapy , Plant Extracts/administration & dosage , Tea , Adiponectin/blood , Adult , Bilirubin/blood , Blood Glucose/drug effects , Body Composition/drug effects , Body Mass Index , Cardiometabolic Risk Factors , Cholesterol/blood , Double-Blind Method , Energy Metabolism/drug effects , Enzymes/blood , Exercise/physiology , Fatty Acids, Nonesterified/blood , Female , Glycerol/blood , Humans , Insulin/blood , Leptin/blood , Male , Middle Aged , Overweight/physiopathology , Oxidation-Reduction/drug effects , Oxygen Consumption/drug effectsABSTRACT
BACKGROUND: An efficient strategy for programming dendritic cells (DCs) for cancer immunotherapy is the optimization of their maturation so that they can efficiently stimulate cancer-specific T cell responses. Interleukin (IL)-4 has appeared as an essential cytokine, widely used in vitro with granulocyte macrophage-colony stimulating factor (GM-CSF) to differentiate monocytes into immature DCs (iDC) and to prevent macrophage formation. Conflicting data have been published regarding the effect of IL-4 on functional DC maturation. To further understand IL-4's effects on DC maturation and function in vitro, we choose the most commonly used maturation factor tumor necrosis factor (TNF)-α. METHODS: Human monocyte-derived iDC were treated for 48 h with GM-CSF and TNF-α in the presence (IL-4(+)-DC) or absence (IL-4(-)-DC) of IL-4 and functions of both DC populations were compared. RESULTS: On mixed lymphocyte reaction assay, IL-4(+)-DC were less potent than IL-4(-)-DC at inducing the proliferation of allogeneic CD4(+) T cells and the proportion of activated T cells expressing CD69 and/or CD25 was smaller. Interleukin-4 reduced the cell-surface expression of TNF-α-induced DC maturation markers CD83, CD86, HLA-DR and CD25 and generated a heterogeneous population of DCs. IL-4(+)-DC secreted less IL-12 and more IL-10 than IL-4(-)-DC following activation by soluble CD40L, and IL-4(+)-DC-activated T cells secreted lesser amounts of T helper (Th) 1 cytokines (IL-2 and interferon-γ). Importantly, IL-4 impaired the in vitro migratory capacity of DCs in response to CCL21 and CCL19 chemokines. This effect was related to reduced expression of CCR7 at both mRNA and protein levels. CONCLUSION: Interleukin-4 used with GM-CSF and TNF-α during the maturation of DCs in vitro impaired DC functions and disturbed the maturation effect of TNF-α. Finally, our study reinforces the view that the quality of the DC maturation stimulus, which regulates DC migration and cytokine production, may be a decisive feature of the immunogenicity of DCs.
Subject(s)
Cell Differentiation/drug effects , Dendritic Cells/cytology , Tumor Necrosis Factor-alpha/pharmacology , Biomarkers/metabolism , CD4-Positive T-Lymphocytes/drug effects , Cell Movement/drug effects , Cell Proliferation/drug effects , Chemokines/pharmacology , Dendritic Cells/drug effects , Dendritic Cells/metabolism , Humans , Interleukin-12/metabolism , Interleukin-4/metabolism , Lymphocyte Activation/drug effects , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, CCR7/genetics , Receptors, CCR7/metabolism , Th1 Cells/drug effectsABSTRACT
BACKGROUND: After resection surgery for Crohn's disease, recurrence of endoscopic lesions at the site of the anastomosis or in the neoterminal ileum is graded according to the Rutgeerts score (RS). The goal of this study was to test the interobserver variability for RS. METHODS: Thirteen trained endoscopists evaluated the RS on 39 videotapes of patients who had undergone resection for Crohn's disease with an ileocolonic anastomosis 6 months earlier. Videotapes were randomly assigned to endoscopists through a balanced incomplete block design. Each videotape was scored independently by four endoscopists, and each endoscopist evaluated 12 videotapes, making a total of 156 videotape assessments. Reproducibility levels of the RS were assessed through unweighted kappa estimates among multiple raters. The proportion of inappropriate therapeutic initiation was estimated by randomly selecting one endoscopist for each videorecording, assuming that the majority of endoscopists correctly classified endoscopic recurrence. RESULTS: The kappa estimates were 0.43 (95% confidence interval: 0.33-0.52) for the RS on a 5-grade scale, 0.47 (0.28-0.66) for RS < i2 vs. ≥ i2, and 0.64 (0.42-0.85) for RS ≤ i2 vs. > i2. The percentages of inappropriate therapeutic initiation were 12.8% (3.8-21.9) when initiation was triggered by a RS ≥ i2 and 8.3% (1.1-15.6) when initiation was triggered by a RS > i2 (p = 0.41). CONCLUSION: The reproducibility of the RS was moderate, especially when differentiating
Subject(s)
Colectomy , Colon/diagnostic imaging , Crohn Disease/diagnostic imaging , Crohn Disease/surgery , Endoscopy, Gastrointestinal , Health Status Indicators , Ileum/diagnostic imaging , Adult , Aftercare , Anastomosis, Surgical , Colon/surgery , Female , Follow-Up Studies , Humans , Ileum/surgery , Male , Observer Variation , Recurrence , Reproducibility of Results , Video RecordingABSTRACT
With the vast amount of medical data being generated on an electronic basis, to ensure that individual patient information is properly linked across multiple sources, efficient patient matching algorithms are critical. We describe a novel naturalistic approach that is a hybrid of both deterministic (exact) and probabilistic ("close") systems that allows for manual adjudication of cases where necessary, but whose basis stems from the thought processes that a rational individual would follow in the comparison of medical records. A validation of this algorithm using large databases from two disparate sources demonstrates that the naturalistic approach can largely eliminate false positives (false matches) and false negatives (false mismatches).
Subject(s)
Algorithms , Datasets as Topic/trends , Patient Identification Systems/methods , Patient Selection , Humans , Medical Record Linkage/methodsABSTRACT
BACKGROUND: Different studies have described the successful use of recombinant lactic acid bacteria (recLAB) to deliver anti-inflammatory molecules at the mucosal level to treat Inflammatory Bowel Disease (IBD). METHODS: In order to identify the best strategy to treat IBD using recLAB, we compared the efficacy of different recombinant strains of Lactococcus lactis (the model LAB) secreting two types of anti-inflammatory molecules: cytokines (IL-10 and TGF-ß1) and serine protease inhibitors (Elafin and Secretory Leukocyte Protease Inhibitor: SLPI), using a dextran sulfate sodium (DSS)-induced mouse model of colitis. RESULTS: Our results show that oral administration of recombinant L. lactis strains expressing either IL-10 or TGF-ß1 display moderate anti-inflammatory effects in inflamed mice and only for some clinical parameters. In contrast, delivery of either serine protease inhibitors Elafin or SLPI by recLAB led to a significant reduction of intestinal inflammation for all clinical parameters tested. Since the best results were obtained with Elafin-producing L. lactis strain, we then tried to enhance Elafin expression and hence its delivery rate by producing it in a L. lactis mutant strain inactivated in its major housekeeping protease, HtrA. Strikingly, a higher reduction of intestinal inflammation in DSS-treated mice was observed with the Elafin-overproducing htrA strain suggesting a dose-dependent Elafin effect. CONCLUSIONS: Altogether, these results strongly suggest that serine protease inhibitors are the most efficient anti-inflammatory molecules to be delivered by recLAB at the mucosal level for IBD treatment.
Subject(s)
Interleukin-10/metabolism , Lactococcus lactis/metabolism , Serine Proteinase Inhibitors/metabolism , Transforming Growth Factor beta/metabolism , Administration, Oral , Animals , Colitis/microbiology , Colitis/pathology , Colitis/therapy , Disease Models, Animal , Elafin/genetics , Elafin/metabolism , Gene Expression/drug effects , Interleukin-10/genetics , Mice , Mice, Inbred C57BL , Nisin/pharmacology , Secretory Leukocyte Peptidase Inhibitor/genetics , Secretory Leukocyte Peptidase Inhibitor/metabolism , Serine Proteinase Inhibitors/genetics , Transforming Growth Factor beta/geneticsABSTRACT
Elafin, a natural protease inhibitor expressed in healthy intestinal mucosa, has pleiotropic anti-inflammatory properties in vitro and in animal models. We found that mucosal expression of Elafin is diminished in patients with inflammatory bowel disease (IBD). This defect is associated with increased elastolytic activity (elastase-like proteolysis) in colon tissue. We engineered two food-grade strains of lactic acid bacteria (LAB) to express and deliver Elafin to the site of inflammation in the colon to assess the potential therapeutic benefits of the Elafin-expressing LAB. In mouse models of acute and chronic colitis, oral administration of Elafin-expressing LAB decreased elastolytic activity and inflammation and restored intestinal homeostasis. Furthermore, when cultures of human intestinal epithelial cells were treated with LAB secreting Elafin, the inflamed epithelium was protected from increased intestinal permeability and from the release of cytokines and chemokines, both of which are characteristic of intestinal dysfunction associated with IBD. Together, these results suggest that oral delivery of LAB secreting Elafin may be useful for treating IBD in humans.
Subject(s)
Bacteria/metabolism , Colon/immunology , Colon/microbiology , Elafin/metabolism , Inflammation/prevention & control , Animals , Bacteria/genetics , Humans , In Vitro Techniques , Inflammatory Bowel Diseases/metabolism , Intestinal Mucosa , MiceABSTRACT
Proteases and proteinase-activated receptor (PAR) activation are involved in several intestinal inflammatory conditions. We hypothesized that serine proteases and PAR activation could also modulate the intestinal injury induced by ischemia-reperfusion (I-R). C57Bl/6 mice were subjected to 90 minutes of intestinal ischemia followed or not by reperfusion. Sham-operated animals served as controls. After ischemia, plasma and tissue serine protease activity levels were increased compared to the activity measured in plasma and tissues from sham-operated mice. This increase was maintained or further enhanced after 2 and 5 hours of reperfusion, respectively. Trypsin (25 kDa) was detected in tissues both after ischemia and 2 hours of reperfusion. Treatment with FUT-175 (10 mg/kg), a potent serine protease inhibitor, increased survival after I-R, inhibited tissue protease activity, and significantly decreased intestinal myeloperoxidase (MPO) activity and chemokine and adhesion molecule expression. We investigated whether serine proteases modulate granulocyte recruitment by a PAR-dependent mechanism. MPO levels and adhesion molecule expression were significantly reduced in I-R groups pre-treated with the PAR(1) antagonist SCH-79797 (5 mg/kg) and in Par(2)(-/-)mice, compared, respectively, to vehicle-treated group and wild-type littermates. Thus, increased proteolytic activity and PAR activation play a pathogenic role in intestinal I-R injury. Inhibition of PAR-activating serine proteases could be beneficial to reduce post-ischemic intestinal inflammation.
Subject(s)
Granulocytes/physiology , Intestine, Small/blood supply , Ischemia/enzymology , Reperfusion Injury/prevention & control , Serine Proteinase Inhibitors/pharmacology , Animals , Benzamidines , Chemokines/metabolism , Cysteine Proteinase Inhibitors/pharmacology , Granulocytes/enzymology , Guanidines/pharmacology , Ischemia/pathology , Leucine/analogs & derivatives , Leucine/pharmacology , Male , Mice , Mice, Inbred C57BL , Peroxidase/metabolism , Protease Inhibitors/pharmacology , Receptor, PAR-1/metabolism , Receptor, PAR-2/metabolism , Reperfusion Injury/enzymology , Reperfusion Injury/pathology , Trypsin/metabolism , alpha-Macroglobulins/metabolismABSTRACT
OBJECTIVE: To determine whether activation of transient receptor potential vanilloid 4 (TRPV-4) induces inflammation in the rat temporomandibular joint (TMJ), and to assess the effects of TRPV-4 agonists and proinflammatory mediators, such as a protease-activated receptor 2 (PAR-2) agonist, on TRPV-4 responses. METHODS: Four hours after intraarticular injection of carrageenan into the rat joints, expression of TRPV-4 and PAR-2 in trigeminal ganglion (TG) neurons and in the TMJs were evaluated by real-time reverse transcription-polymerase chain reaction and immunofluorescence, followed by confocal microscopy. The functionality of TRPV-4 and its sensitization by a PAR-2-activating peptide (PAR-2-AP) were analyzed by measuring the intracellular Ca(2+) concentration in TMJ fibroblast-like synovial cells or TG neurons. Plasma extravasation, myeloperoxidase activity, and the head-withdrawal threshold (index of mechanical allodynia) were evaluated after intraarticular injection of selective TRPV-4 agonists, either injected alone or coinjected with PAR-2-AP. RESULTS: In the rat TMJs, TRPV-4 and PAR-2 expression levels were up-regulated after the induction of inflammation. Two TRPV-4 agonists specifically activated calcium influx in TMJ fibroblast-like synovial cells or TG neurons. In vivo, the agonists triggered dose-dependent increases in plasma extravasation, myeloperoxidase activity, and mechanical allodynia. In synovial cells or TG neurons, pretreatment with PAR-2-AP potentiated a TRPV-4 agonist-induced increase in [Ca(2+) ](i) . In addition, TRPV-4 agonist-induced inflammation was potentiated by PAR-2-AP in vivo. CONCLUSION: In this rat model, TRPV-4 is expressed and functional in TG neurons and synovial cells, and activation of TRPV-4 in vivo causes inflammation in the TMJ. Proinflammatory mediators, such as PAR-2 agonists, sensitize the activity of TRPV-4. These results identify TRPV-4 as an important signal of inflammation in the joint.
Subject(s)
Inflammation/metabolism , Neurons/metabolism , Synovial Membrane/metabolism , TRPV Cation Channels/metabolism , Temporomandibular Joint/metabolism , Animals , Calcium/metabolism , Carrageenan , Gene Expression , Hyperalgesia/genetics , Hyperalgesia/metabolism , Inflammation/chemically induced , Male , Neurons/drug effects , Oligopeptides/pharmacology , Phorbol Esters/pharmacology , Rats , Rats, Wistar , Receptor, PAR-2/agonists , Receptor, PAR-2/genetics , Receptor, PAR-2/metabolism , Synovial Membrane/drug effects , TRPV Cation Channels/agonists , TRPV Cation Channels/genetics , Temporomandibular Joint/drug effectsABSTRACT
BACKGROUND & AIMS: Colonic tissues of patients with inflammatory bowel disease have been reported to have increased proteolytic activity, but no studies have clearly addressed the role of the balance between proteases and antiproteases in the pathogenesis of colitis. We investigated the role of Elafin, a serine protease inhibitor expressed by skin and mucosal surfaces in human inflammatory conditions, and the proteases neutrophil elastase (NE) and proteinase-3 (PR-3) in mice with colitis. METHODS: We studied mice with heterozygous disruptions in NE and PR-3, mice that express human elafin (an inhibitor of NE and PR-3), and naïve mice that received intracolonic adenoviral vectors that express elafin. Trinitrobenzene sulfonic acid (TNBS) or dextran sodium sulphate (DSS) was used to induce colitis. Protease, cytokine levels, and NF-κB activity were measured in colons of mice. Caco-2 and HT29 cells were studied in assays for cytokine expression, permeability, and NF-κB activity. RESULTS: Elafin expression or delivery re-equilibrated the proteolytic balance in inflamed colons of mice. In mice given TNBS or DSS, transgenic expression of elafin or disruption of NE and PR-3 protected against the development of colitis. Similarly, adenoviral delivery of Elafin significantly inhibited inflammatory parameters. Elafin modulated a variety of inflammatory mediators in vitro and in vivo and strengthened intestinal epithelial barrier functions. CONCLUSIONS: The protease inhibitor Elafin prevents intestinal inflammation in mouse models of colitis and might be developed as a therapeutic agent for inflammatory bowel disease.
Subject(s)
Colitis , Elafin/genetics , Genetic Therapy/methods , Leukocyte Elastase/metabolism , Protease Inhibitors/metabolism , Adenoviridae/genetics , Animals , Caco-2 Cells , Chemokines/metabolism , Colitis/genetics , Colitis/metabolism , Colitis/therapy , Cytokines/metabolism , Elafin/metabolism , Gene Expression/physiology , HT29 Cells , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Myeloblastin/metabolism , NF-kappa B/metabolism , Neutrophils/enzymology , Neutrophils/immunology , Serine Proteinase Inhibitors/metabolismABSTRACT
BACKGROUND & AIMS: Ligand-gated calcium channels have been reported to be involved in the pathogenesis of inflammatory bowel disease. One family member, transient receptor potential vanilloid 4 (TRPV4), is activated by arachidonic acid derivatives that might be released on inflammation, yet its role in gastrointestinal inflammation has not been characterized. We investigated whether TRPV4 activation participates in intestinal inflammation and its expression and functions in the gastrointestinal tract. METHODS: TRPV4 expression was studied in human colon samples, human intestinal epithelial cell lines (Caco-2 and T84), and inflamed colons of mice. Calcium mobilization and cytokine release were analyzed in intestinal epithelial cells exposed to the selective TRPV4 agonist 4α-phorbol-12,13-didecanoate (4αPDD). Mice were killed 3, 6, or 24 hours after intracolonic administration of 4αPDD; inflammatory parameters were measured in their colon tissues, and paracellular colonic permeability was measured by the passage of (51)Cr-EDTA from the colon lumen to the blood. RESULTS: High levels of TRPV4 were detected in Caco-2 cells and in epithelial cells of human colon tissue samples; its expression was up-regulated in colons from inflamed mice compared with noninflamed control mice. Administration of 4αPDD to Caco-2 and T84 cells caused a dose-dependent increase in intracellular calcium concentration and chemokine release. In mice, intracolonic administration of 4αPDD caused colitis to develop 3 to 6 hours later; inflammation resolved by 24 hours. Increased colonic permeability was observed in vivo 3 hours after intracolonic administration of 4αPDD. CONCLUSIONS: TRPV4 is expressed and functional in intestinal epithelial cells; its activation in the gastrointestinal tract causes increases in intracellular calcium concentrations, chemokine release, and colitis.
Subject(s)
Colitis/immunology , Intestines/immunology , TRPV Cation Channels/immunology , Animals , Caco-2 Cells , Cell Line , Chemokines/metabolism , Colitis/chemically induced , Humans , Intestines/drug effects , Male , Mice , Mice, Inbred C57BL , Phorbol Esters/toxicity , Signal Transduction/drug effects , TRPV Cation Channels/agonists , TRPV Cation Channels/analysisABSTRACT
Serine proteases such as thrombin, trypsin and mast cell tryptase can act on different cell types through protease-activated receptors (PARs). These receptors have been shown to be implicated in several phenomena such as inflammation, platelet activation, immune response and atherosclerosis. Several studies recently reported PARs expression on neurons and some of them demonstrated that these receptors could interfere with nociception. The contribution of PAR(1) to inflammatory pain and the mechanism involved in this phenomenon were investigated. Intraplantar injection of PAR(1) agonist increased withdrawal latency and reduced response frequency to von Frey filaments, thus inhibiting nociceptive response to both mechanical and thermal stimuli in mice. PAR(1) agonist also reduced carrageenan-induced inflammatory hyperalgesia. The anti-nociceptive effects of PAR(1) agonist were mediated by endogenous opioids, as this effect was inhibited by local injection of naloxone methiodide, and because intraplantar injection of PAR(1) agonist increased mRNA expression of the endogenous opioid precursor proenkephalin. However, PAR(1) agonist was not able to inhibit calcium signals in isolated sensory neurons exposed to pro-nociceptive agents. Finally, despite similar inflammatory parameters, PAR(1)-deficient mice showed a strong potentiation of inflammatory hyperalgesia induced by the intraplantar injection of either formalin or carrageenan, or in the chronic model of collagen-induced arthritis, compared to wild-type mice. This study highlights a previously unknown endogenous mechanism of analgesia, showing a central role for the thrombin receptor PAR(1) in the regulation of inflammatory pain and as an activator of opioid pathways.
Subject(s)
Inflammation/physiopathology , Opioid Peptides/physiology , Pain/physiopathology , Receptors, Thrombin/physiology , Animals , Calcium/metabolism , Foot , Hyperalgesia/chemically induced , Hyperalgesia/pathology , Immunohistochemistry , Inflammation/chemically induced , Inflammation/complications , Injections , Male , Mice , Mice, Inbred C57BL , Nociceptors/drug effects , Oligopeptides/administration & dosage , Oligopeptides/pharmacology , Pain/chemically induced , Pain/etiology , Pain Measurement/drug effects , Receptor, PAR-1/agonists , Receptor, PAR-1/physiology , Receptors, Opioid/drug effects , Reverse Transcriptase Polymerase Chain Reaction , Sensory Receptor Cells/drug effects , Signal Transduction/physiologyABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease. The main cause of NAFLD is insulin resistance; therefore, it is necessary to assess liver injury in patients with overweight and insulin resistance-related complications. The two main forms of primary NAFLD, steatosis and steatohepatitis (NASH), most likely represent distinct conditions. At present, the diagnosis of NASH presents drawbacks, including the lack of consensus regarding diagnostic criteria, sampling variability, cost and the invasiveness of the procedure. Based on a critical assessment of the literature, this article aims to determine whether the diagnosis of NASH is clinically useful, and whether it is feasible with noninvasive strategies instead of liver biopsy. A noninvasive diagnosis of NASH would facilitate screening and monitoring of populations at risk, as well as the conduct of therapeutic trials.
ABSTRACT
BACKGROUND: Probiotic bacteria have been shown to modulate immune responses and could have therapeutic effects in allergic and inflammatory disorders. However, the signaling pathways engaged by probiotics are poorly understood. We have previously reported that a fermentation product from Bifidobacterium breve C50 (BbC50sn) could induce maturation, high IL-10 production and prolonged survival of DCs via a TLR2 pathway. We therefore studied the roles of mitogen-activated protein kinases (MAPK), glycogen synthase kinase-3 (GSK3) and phosphatidylinositol 3-kinase (PI3K) pathways on biological functions of human monocyte-derived DCs treated with BbC50sn. METHODOLOGY/PRINCIPAL FINDINGS: DCs were differentiated from human monocytes with IL-4 and GM-CSF for 5 days and cultured with BbC50sn, lipopolysaccharide (LPS) or Zymosan, with or without specific inhibitors of p38MAPK (SB203580), ERK (PD98059), PI3K (LY294002) and GSK3 (SB216763). We found that 1) the PI3K pathway was positively involved in the prolonged DC survival induced by BbC50sn, LPS and Zymosan in contrast to p38MAPK and GSK3 which negatively regulated DC survival; 2) p38MAPK and PI3K were positively involved in DC maturation, in contrast to ERK and GSK3 which negatively regulated DC maturation; 3) ERK and PI3K were positively involved in DC-IL-10 production, in contrast to GSK3 that was positively involved in DC-IL-12 production whereas p38MAPK was positively involved in both; 4) BbC50sn induced a PI3K/Akt phosphorylation similar to Zymosan and a p38MAPK phosphorylation similar to LPS. CONCLUSION/SIGNIFICANCE: We report for the first time that a fermentation product of a bifidobacteria can differentially activate MAPK, GSK3 and PI3K in order to modulate DC biological functions. These results give new insights on the fine-tuned balance between the maintenance of normal mucosal homeostasis to commensal and probiotic bacteria and the specific inflammatory immune responses to pathogen bacteria.
Subject(s)
Bifidobacterium/metabolism , Dendritic Cells/cytology , Bifidobacterium/genetics , Dendritic Cells/microbiology , Fermentation , Glycogen Synthase Kinase 3/metabolism , Humans , Hypersensitivity , Immune System , Inflammation , Interleukin-10/metabolism , MAP Kinase Signaling System , Models, Biological , Monocytes/cytology , Phosphatidylinositol 3-Kinases/metabolism , Signal Transduction , Toll-Like Receptor 2/metabolismABSTRACT
BACKGROUND: Commensal gut bacteria are essential for the development and maintenance of the gut's immune system. Some bacteria strains, such as Lactobacillus and Bifidobacterium species, have been reported to provide protection from allergic and inflammatory bowel diseases. However, the interactions between these commensal bacteria and the immune system are largely unknown. OBJECTIVE: We studied the effects of a supernatant from the culture of B breve C50 (BbC50) on the maturation, activation, and survival of human dendritic cells (DCs). METHODS: DCs were differentiated from human monocytes with IL-4 and GM-CSF for 5 days and cultured with BbC50 supernatant (BbC50SN) or LPS for 2 days. RESULTS: BbC50SN induced DC maturation, with increase in CD83, CD86, and HLA-DR expression. We also showed, for the first time, that BbC50SN prolonged DC survival, with high IL-10 and low IL-12 production compared with that seen in LPS-DCs. Moreover, BbC50SN inhibited the effects of LPS on DCs, both in terms of IL-12 production and in terms of survival. The prolonged DC survival was independent of IL-10 production and nuclear factor kappaB pathway but was associated with an upregulation of Bcl-xL and Phospho-Bad. Finally, BbC50SN induced activation of Toll-like receptor 2 (TLR2)-transfected cells in contrast to TLR4-, TLR7-, and TLR9-transfected cells. CONCLUSION: The supernatant of B breve C50 can induce DC maturation and prolonged DC survival through TLR2, with high IL-10 production. These properties might correspond to a regulatory DC profile, which could limit the excessive TH1 response and control the excessive TH2 polarization observed in atopic newborns.
Subject(s)
Bifidobacterium/immunology , Dendritic Cells/immunology , Toll-Like Receptor 2/immunology , Cell Line , Cell Proliferation , Cell Survival/immunology , Humans , Immunity, Cellular/immunology , Interleukin-10/immunology , Signal Transduction/immunologyABSTRACT
We have previously reported that the CD4+ T lymphocyte response against nuclear human CMV IE1 protein depends in part on endogenous MHC class II presentation. To optimize presentation by HLA-DR of the nuclear IE1 protein and increase the response by CD4+ T cells, we have constructed two different adenovirus vectors containing mutant versions of IE1, containing a HLA-DR3 epitope, fused to GFP. The first construct consisted of a sequence of 46 aa encoded by exon 4, called GFP-IE1 (86-131). The second construct consisted of the whole IE1 mutated on exon 4 nuclear localization signals, identified in this study, and deleted of already known exon 2 nuclear localization signals (GFP-IE1M). Both of these IE1 vectors expressed proteins with cytoplasmic localization, as evidenced by GFP expression, as opposed to control GFP-IE1, which was nuclear. GFP-IE1 (86-131) induced IE1-specific CD4+ T cell clone response that was >30-fold more potent than that against GFP-IE1 and GFP-IE1M. The CD4+ T cell response was due to endogenous presentation followed by exogenous presentation at later time points. Presentation was dependent on both proteasome and acidic compartments. GFP-IE1 (86-131) was rapidly degraded by the APC, which may account for better presentation. Our data show potentiation of the CD4+ T cell response to a specific epitope through shortening and relocation of an otherwise nuclear protein and suggest applications in vaccination.